1 / 14

MEDICINES OPTIMISATION IN DIABETES Yvonne Parker Medicines Optimisation Pharmacist

MEDICINES OPTIMISATION IN DIABETES Yvonne Parker Medicines Optimisation Pharmacist Stoke-on-Trent CCG. Current Prescribing Trends. Figures taken from PrescQIPP Drugs used for diabetes snapshot 2014/15 – April to January. Growth by BNF chapter – Actual Growth Cost.

messersmith
Télécharger la présentation

MEDICINES OPTIMISATION IN DIABETES Yvonne Parker Medicines Optimisation Pharmacist

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MEDICINES OPTIMISATION IN DIABETES Yvonne Parker Medicines Optimisation Pharmacist Stoke-on-Trent CCG

  2. Current Prescribing Trends Figures taken from PrescQIPP Drugs used for diabetes snapshot 2014/15 – April to January

  3. Growth by BNF chapter – Actual Growth Cost Top 6 BNF chapters (highest to lowest growth cost):

  4. Endocrine System Growth Actual growth April to February 13/14 vs 14/15

  5. Top 10 Diabetes Drugs/Reagents by Cost

  6. Main areas of concern Stoke-on-Trent • 2,000% (£18,500) increase in insulin degludec • 250% (£5,600) increase in combination product sitagliptin/metformin (Janumet) North Staffs • 365% (£10,000) increase in insulin degludec • 11% (£10,000) increase in liraglutide

  7. Main areas of improvement Stoke-on-Trent • Decreased spend on non-formulary drugs • Decreased spend on BGTS • Decreased spend for 3 combination products North Staffs • Decreased spend on non-formulary drugs • Decreased spend for 3 combination products

  8. North Staffordshire Joint Formulary • AIMS: • To promote safe, effective and economic prescribing in both primary and secondary care • Help to ensure seamless prescribing, thereby reducing possible errors and confusion • Each section approved by the North Staffordshire and Stoke-on-Trent Area Prescribing Committee

  9. Medicines are categorised according to a traffic light system The formulary can be found at: http://www.stokeccg.nhs.uk/joint-formulary

  10. GLP-1 mimetic prescribing and ESCAs • 1st line – Byetta (exenatide twice daily) • 2nd line – Bydureon (exenatide once weekly) • 3rd line – Victoza (liraglutide once daily) Essential Shared Care Agreements (ESCAs) set out specialist, GP and patient responsibilities and are required due to the amber 1 classification of GLP1s on the formulary

  11. GLP-1 mimetic prescribing and ESCAs 7 GP practices in Stoke are taking part in the GLP1 LIS service Prescribing needs to be in line with NICE guidance • Triple therapy – 1.0% reduction in HbA1c and 3% reduction in weight 6 months after initiation • Dual therapy – 1.0% reduction in HbA1c 6 months after initiation

  12. Guidelines for diabetes • Management of adults with diabetes mellitus – Guidelines for clinical care • At-a-glance guide for self monitoring blood glucose (SMBG) in diabetes • Patient guide for self monitoring of blood glucose (SMBG) in diabetes • At-a-glance guide for treatment with a 3rd line oral agent for patients with type 2 diabetes

  13. Medicines OptimisationProjects • Prescribing of WaveSense JAZZ BGTS and supplying the meter to all suitable patients • Prescribing of Omnican Fine or GlucoRxFinePoint pen needles to all suitable patients • A review of the prescribing of 3rd line oral antidiabetic agents in the management of type 2 diabetes

  14. Any questions?

More Related